Vertex gets good news for RA drug

Vertex Pharmaceuticals announced that its investigational rheumatoid arthritis drug VX-702 met the primary objectives in a 12-week Phase II study. The company plans to initiate clinical studies of VX-702 in combination with methotrexate by mid-2006. "Demonstration of clear effects on the signs and symptoms of RA, in conjunction with good tolerability with three months of treatment, represents a major achievement for the VX-702 clinical program," commented John Alam, M.D., Vertex's chief medical officer.

- see this press release for more

ALSO: U.K.-based Avidex announced that its rheumatoid arthritis drug RhuDex has successfully completed two Phase I studies. Release